“…It is not surprising to observe inhibition of SARS-CoV-2 by geldanamycin, given that a large number of viruses have been reported subject to geldanamycin inhibition. These include encephalomyocarditis virus (EMCV) (59), bombyx mori nucleopolyhedrovirus (60–62), pseudorabies virus (63), H5N1 influenza A virus (64), porcine circovirus 2 (65), chikungunya virus (66, 67), porcine reproductive and respiratory syndrome virus (68), enterovirus 71 (69, 70), herpes simplex virus type 2 (71), human cytomegalovirus (71, 72), Theiler’s murine encephalomyelitis virus (73), Ebola virus (74), hepatitis E virus (75), influenza virus (76), hepadnavirus (77), hepatitis B virus (77), flock house virus (78), vesicular stomatitis virus (79), hepatitis C virus (80, 81), herpes simplex virus type 1 (82, 83), vaccinia virus (84), RT and Rauscher leukemia virus (85). This broad antiviral activity of geldanamycin is primarily attributed to its antagonism of HSP90.…”